Published in
Elsevier, Journal of Clinical Virology, 2(54), p. 194-196, 2012
DOI: 10.1016/j.jcv.2012.02.008
Links
Tools
Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection
Journal article published in 2012 by
David Boutolleau,
Ana Canestri,
Sonia Burrel,
Marc Wirden,
Sophie Seang,
Cyril Clavel-Osorio,
Anne-Geneviève Marcelin 
,
Christine Katlama,
Henri Agut
,
Christine Katlama,
Henri Agut
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Foscarnet (FOS) is a pyrophosphate analogue that inhibits both cytomegalovirus (CMV) and human immunodeficiency virus (HIV) replication. We describe herein the emergence of CMV resistance to FOS in a 54-year-old man receiving FOS salvage therapy because of multidrug-resistant HIV-1 infection. Oral valganciclovir (VGCV) treatment allowed subsequently the improvement of FOS-resistant CMV infection.